Schröder, Dominik

[["dc.bibliographiccitation.journal","Frontiers in Public Health"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Schröder, Dominik; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Heesen, Gloria; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Heinemann, Stephanie; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Hummers, Eva; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Jablonka, Alexandra; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Steffens, Sandra; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Mikuteit, Marie; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Niewolik, Jacqueline; 2Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany"],["dc.contributor.affiliation","Overbeck, Tobias R.; 4Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Kallusky, Jonathan; 4Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Müller, Frank; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Kallusky, Jonathan"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2022-04-26T12:34:44Z"],["dc.date.available","2022-04-26T12:34:44Z"],["dc.date.issued","2022"],["dc.date.updated","2022-05-10T16:09:22Z"],["dc.description.abstract","Background: Restrictions to contain the COVID-19 pandemic affect the social participation of people worldwide. Especially those at high risk for a severe disease tend to abstain from social gatherings. While there are a few questionnaires to measure social participation in elderly or chronic patients, a valid survey instrument that includes pandemic-related social participation is needed. Methods We developed a social participation questionnaire that aims to assess pandemic-related restrictions in social participation. Items were developed using a theory and literature-based approach and then compiled in a discursive process involving experts and lay people. This was followed by the validation of the questionnaire through a cross-sectional survey on 431 individuals. Items with low item-total correlations and low factor loadings using exploratory factor analysis [EFA] were excluded. Using EFA on the remaining items, the factor structure was retrieved and tested with a confirmatory factor analysis [CFA]. Internal consistency was assessed with Chronbachs α. Results Initially, 27 items were developed which were used for validation. 13 items were excluded due to low item-total correlations and factors loadings. EFA of the remaining 14 items revealed three factors which were identified as domains “active social participation,” “wellbeing,” and “restrictions”. CFA showed an acceptable model fit using the three-dimensional structure. Chronbachs α of 0.81 and McDonalds Ω of 0.87 indicate good internal consistency. Correlation analysis showed an association between the developed questionnaire and previously-established participation and mental health scales. Conclusion This study suggests that our 14 item questionnaire is of high reliability and validity and can be used to measure social participation during a pandemic."],["dc.identifier.doi","10.3389/fpubh.2022.831087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106769"],["dc.language.iso","en"],["dc.publisher","Frontiers Media S.A."],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.issn","2296-2565"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Development and Validation of a Questionnaire to Assess Social Participation of High Risk-Adults in Germany During the COVID-19 Pandemic"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Demmer, Iris"],["dc.contributor.author","El-Sayed, Iman"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Königs, Gloria"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Müllenmeister, Christina"],["dc.contributor.author","Nußbaum, Kathrin"],["dc.contributor.author","Schmachtenberg, Tim"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.editor","Roder, Sascha"],["dc.contributor.editorcorporation","Sascha Roder"],["dc.date.accessioned","2022-11-07T10:03:36Z"],["dc.date.available","2022-11-07T10:03:36Z"],["dc.date.issued","2022"],["dc.identifier.isbn","978-3-00-073127-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/116942"],["dc.language.iso","de"],["dc.publisher","Universitätsmedizin Göttingen"],["dc.publisher.place","Göttingen"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","(Er-)Leben mit Long COVID"],["dc.title.subtitle","Projektergebnisse einer qualitativen Studie bildhaft interpretiert"],["dc.type","book"],["dc.type.internalPublication","yes"],["dc.type.subtype","collection_book"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Zeitschrift für Rheumatologie"],["dc.bibliographiccitation.lastpage","11"],["dc.bibliographiccitation.volume","May 6"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Noack, Eva Maria"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Schröder, Dominik"],["dc.creator.author","Frank Müller"],["dc.creator.author","Stephanie Heinemann"],["dc.creator.author","Eva Hummers"],["dc.creator.author","Eva Maria Noack"],["dc.creator.author","Gloria Heesen"],["dc.creator.author","Alexandra Dopfer-Jablonka"],["dc.creator.author","Marie Mikuteit"],["dc.creator.author","Jacqueline Niewolik"],["dc.creator.author","Sandra Steffens"],["dc.creator.author","Dominik Schröder"],["dc.date.accessioned","2022-05-07T01:54:33Z"],["dc.date.available","2022-05-07T01:54:33Z"],["dc.date.issued","2022"],["dc.description.abstract","Immunocompromised people are less likely to be vaccinated, despite an increased benefit of many vaccinations in terms of benefit-risk assessment, including the vaccines against SARS CoV-2 (COVID-19). Attitudes, expectations, and experiences with previous vaccinations influence the decision to get vaccinated."],["dc.identifier.doi","10.1007/s00393-022-01213-5"],["dc.identifier.pmid","35523964"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108140"],["dc.identifier.url","https://publications.goettingen-research-online.de/handle/2/107676"],["dc.language.iso","de"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","1435-1250"],["dc.relation.issn","0340-1855"],["dc.relation.issn","1435-1250"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.subject.gro","Immunosuppression; SARS-CoV‑2; Vaccination; Vaccination acceptance; Vaccine Uptake; Vaccine hesitancy"],["dc.title","Impfeinstellung, Erwartungen und Impferfahrung von Immunsupprimierten bei COVID-19 Impfungen - Ergebnisse einer Längsschnittstudie"],["dc.title.alternative","Immunosuppressed people's beliefs, expectations, and experiences with COVID-19 vaccinations: Results of a longitudinal study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","403"],["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Infectious Diseases"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Stankov, Metodi V."],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Roder, Sascha"],["dc.contributor.author","Klawonn, Frank"],["dc.contributor.author","Vahldiek, Kai"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Kallusky, Jonathan"],["dc.contributor.author","Falk, Christine S."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Heinemann, Stephanie"],["dc.date.accessioned","2022-04-29T07:33:23Z"],["dc.date.accessioned","2022-08-12T12:57:45Z"],["dc.date.available","2022-04-29T07:33:23Z"],["dc.date.available","2022-08-12T12:57:45Z"],["dc.date.issued","2022-04-25"],["dc.date.updated","2022-07-29T12:00:25Z"],["dc.description.abstract","Background\r\n Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP are taking precautions that may include a reduction of social contacts and participation in activities which they normally enjoy. Furthermore, for these people, there is an uncertainty regarding the effectiveness of the vaccination. The COVID-19 Contact (CoCo) Immune study strives to characterize the immune response to COVID-19 vaccination in immunocompromised, elderly people, and patients with hematological or oncological diseases. The study uses blood-based screenings to monitor the humoral and cellular immune response in these groups after vaccination. Questionnaires and qualitative interviews are used to describe the level of social participation.\r\n \r\n \r\n Methods\r\n The CoCo Immune Study is a mixed methods prospective, longitudinal, observational study at two large university hospitals in Northern Germany. Starting in March 2021, it monitors anti-SARS-CoV-2 immune responses and collects information on social participation in more than 600 participants, at least 18 years old. Inclusion criteria and subcohorts: Participants with (1) regularly intake of immunosuppressive medication (ICP-cohort) or (2) age ≥ 80 years (80 + -cohort). Additionally, patients with current or former (3) myeloid, (4) lymphatic disease or (5) solid tumor under checkpoint inhibition (3–5: HO-cohort). Exclusion criteria: (1) refusal to give informed consent, (2) contraindication to blood testing, (3) inability to declare consent. Participants complete a questionnaire at four different time points: prior to full vaccination, and 1, 6 and 12 months after completed vaccination. In addition, participants draw blood samples themselves or through a local health care provider and send them with their questionnaires per post at the respective time points after vaccination. Patients of the HO cohort dispense additional blood samples at week 3 to 12 and at month 6 to 9 after 2nd vaccination to gain additional knowledge in B and T cell responses. Selected participants are invited to qualitative interviews about social participation.\r\n \r\n \r\n Discussion\r\n This observational study is designed to gain insight into the immune response of people with weakened immune systems and to find out how social participation is affected after COVID-19 vaccination.\r\n Trial registration: This study was registered with German Clinical Trial Registry (registration number: DRKS00023972) on 30th December 2020."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Infectious Diseases. 2022 Apr 25;22(1):403"],["dc.identifier.doi","10.1186/s12879-022-07347-w"],["dc.identifier.pmid","35468758"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106987"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112723"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","1471-2334"],["dc.relation.issn","1471-2334"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","SARS-CoV-2"],["dc.subject","COVID-19"],["dc.subject","Pandemic"],["dc.subject","Humoral and cellular immunity"],["dc.subject","Immunocompromised people"],["dc.subject","Elderly"],["dc.subject","Hematology"],["dc.subject","Solid tumor"],["dc.subject","Checkpoint inhibition"],["dc.subject","Serological testing"],["dc.subject","Coronavirus"],["dc.subject","Social participation"],["dc.subject","Immunogenicity"],["dc.title","SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","97"],["dc.bibliographiccitation.firstpage","97"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European journal of medical research"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Klawonn, Frank"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Behrens, Georg"],["dc.contributor.author","Jablonka, Alexandra"],["dc.contributor.author","Müller, Frank"],["dc.date.accessioned","2022-06-24T08:23:02Z"],["dc.date.available","2022-06-24T08:23:02Z"],["dc.date.issued","2022-06-22"],["dc.date.updated","2022-07-25T11:19:00Z"],["dc.description.abstract","The influence of immunosuppressive therapy on immunogenicity after COVID-19 vaccination remains unclear. This study surveys patients who receive immunosuppressive therapy about whether or not they paused their immunosuppressive medication while receiving SARS-CoV-2 vaccination."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","European Journal of Medical Research. 2022 Jun 22;27(1):97"],["dc.identifier.doi","10.1186/s40001-022-00727-7"],["dc.identifier.pmid","35733228"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/111667"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","2047-783X"],["dc.relation.issn","2047-783X"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","Immunosuppression"],["dc.subject","SARS-CoV-2"],["dc.subject","COVID-19"],["dc.subject","Immunization"],["dc.subject","Immunogenicity"],["dc.subject","Drug compliance"],["dc.subject","Drug adherence"],["dc.title","Who is pausing immunosuppressive medication for COVID-19 vaccination? Results of an exploratory observational trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","9924"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","International Journal of Environmental Research and Public Health"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Homann, Stefanie"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Behrens, Georg"],["dc.contributor.author","Stölting, Andrea"],["dc.contributor.author","Müllenmeister, Christina"],["dc.contributor.author","El-Sayed, Iman"],["dc.contributor.author","Happle, Christine"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Jablonka, Alexandra"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.orcid","0000-0003-3111-621X"],["dc.contributor.orcid","0000-0002-7084-9013"],["dc.contributor.orcid","0000-0002-9496-9423"],["dc.contributor.orcid","0000-0002-3564-4725"],["dc.contributor.orcid","0000-0002-3937-5956"],["dc.contributor.orcid","0000-0002-5500-7416"],["dc.contributor.orcid","0000-0001-7129-100X"],["dc.creator.author","Stefanie Homann"],["dc.creator.author","Marie Mikuteit"],["dc.creator.author","Jacqueline Niewolik"],["dc.creator.author","Georg Behrens"],["dc.creator.author","Andrea Stölting"],["dc.creator.author","Frank Müller"],["dc.creator.author","Dominik Schröder"],["dc.creator.author","Stephanie Heinemann"],["dc.creator.author","Christina Müllenmeister"],["dc.creator.author","Iman El-Sayed"],["dc.creator.author","Christine Happle"],["dc.creator.author","Sandra Steffens"],["dc.creator.author","Alexandra Jablonka"],["dc.date.accessioned","2022-10-13T11:36:39Z"],["dc.date.available","2022-10-13T11:36:39Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Patients who are post-COVID-19 will require more treatment soon. Therefore, it is important to understand the root cause of their psychological and somatic conditions. Previous studies showed contradictory results on the influence of pre-existing mental conditions. The present study examines the influence of these pre-existing conditions and their pre-treatment on the severity of post-COVID-19 symptoms. Methods: This analysis employs questionnaire data from a large study sample in Germany. Overall, 801 participants were included. All participants rated their health status on a scale from 0 to 100. Fatigue, depression, and anxiety were measured using the FAS, PHQ-9, and GAD-7 scales. Results: All pre-pandemic values showed no significant differences between the groups. The current health status was rated similarly by the recovered patients (μ = 80.5 ± 17.0) and the control group (μ = 81.2 ± 18.0) but significantly worse by acutely infected (μ = 59.0 ± 21.5) and post-COVID-19 patients (μ = 54.2 ± 21.1). Fatigue, depression, and anxiety were similar for recovered patients and the control group. By contrast, there were significant differences between the control and the post-COVID-19 groups concerning fatigue (45.9% vs. 93.1%), depression (19.3% vs. 53.8%), and anxiety (19.3% vs. 22.3%). Conclusion: Fatigue and psychological conditions of post-COVID-19 patients are not associated with pre-existing conditions."],["dc.identifier.doi","10.3390/ijerph19169924"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/116305"],["dc.identifier.url","https://www.mdpi.com/1660-4601/19/16/9924"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.issn","1660-4601"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","Effects of Pre-Existing Mental Conditions on Fatigue and Psychological Symptoms Post-COVID-19"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","315"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Primary Care"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Holman, Harland"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Noack, Eva M."],["dc.date.accessioned","2022-12-12T08:14:49Z"],["dc.date.available","2022-12-12T08:14:49Z"],["dc.date.issued","2022-12-06"],["dc.date.updated","2022-12-11T04:11:38Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Providing medical care to newly arrived migrants presents multiple challenges. A major challenge is a lack of a common language in the absence of language interpretation services. We examine the multilingualism of German physicians and clinical psychotherapists providing ambulatory care.\r\n \r\n \r\n Methods\r\n We retrieved publicly available data from the Associations of Statutory Health Insurance Physicians provider registry of three German federal states (Lower Saxony, Saarland, Bavaria). We selected and grouped relevant practice-based disciplines. We used descriptive statistics to analyze the provider’s multilingualism among different disciplines.\r\n \r\n \r\n Results\r\n 69.6% of ambulatory providers offer consultations only in German. 15.5% of providers reported offering consultations in one additional non-German language, and 14.9% in two or more additional languages. Most common additional languages were English (28.6%) and French (9.9%). 1.4% of providers reported offering consultation in at least one language of the Middle Eastern region (Arabic, Dari, Hebrew, Kurdish, Pashtu, Farsi, and Turkish). There were differences in the offered languages between the medical disciplines with the highest mean rates found for gynecologists and obstetricians, urologists, and general surgeons. Psychotherapeutic disciplines offered consultation in other languages significantly less often.\r\n \r\n \r\n Conclusion\r\n Our study suggests a significant numeric mismatch in the number of providers offering consultations in the languages of people seeking protection in Germany. The resulting language barriers are compromising equitable access and quality of care."],["dc.identifier.citation","BMC Primary Care. 2022 Dec 06;23(1):315"],["dc.identifier.doi","10.1186/s12875-022-01926-1"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118498"],["dc.language.iso","en"],["dc.publisher","BioMed Central"],["dc.relation.issn","2731-4553"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights.holder","The Author(s)"],["dc.subject","Language proficiency"],["dc.subject","Primary care"],["dc.subject","Migration"],["dc.subject","Language barrier"],["dc.title","Multilingual competencies among ambulatory care providers in three German Federal States"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Public Health"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Heesen, Gloria; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Schröder, Dominik; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Müller, Frank; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Hummers, Eva; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Klawonn, Frank; 2Department of Computer Science, Ostfalia University of Applied Sciences, Wolfenbuettel, Germany"],["dc.contributor.affiliation","Mikuteit, Marie; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Niewolik, Jacqueline; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Steffens, Sandra; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Cossmann, Anne; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Behrens, Georg; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Dopfer-Jablonka, Alexandra; 4Department of Rheumatology and Immunology, Hannover Medical School, Germany"],["dc.contributor.affiliation","Heinemann, Stephanie; 1Department of General Practice, University Medical Center, Göttingen, Germany"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Klawonn, Frank"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Behrens, Georg"],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Heinemann, Stephanie"],["dc.date.accessioned","2022-06-13T06:22:30Z"],["dc.date.available","2022-06-13T06:22:30Z"],["dc.date.issued","2022-06-10"],["dc.date.updated","2022-06-24T06:43:46Z"],["dc.description.abstract","Immunocompromised persons are at an increased risk for a severe SARS-CoV-2 infection and their safety behaviors may influence their social participation. Vaccinated persons have a lower incidence of infection and severe disease when infected compared to non-vaccinated persons. Therefore, their behavior may change and their social participation may increase after a complete vaccination. The aim of this study was to explore social participation of immunocompromised persons before and after complete COVID-19 vaccination. Between March and September 2021, 274 immunocompromised participants were recruited. Survey data were collected at baseline and follow-up from 194 participants including the Index for the Assessment of Health Impairments [IMET], Patient Health Questionnaire-4 [PHQ-4], subjective health status and quality of life. At baseline, participants were not yet completely vaccinated. Complete vaccination was achieved prior to the follow-up questionnaire. IMET scores decreased significantly at follow-up, indicating a higher social participation after complete vaccination. PHQ-4, subjective health status and quality of life did not differ between baseline and follow-up. There were no significant differences across sociodemographic factors. Significant PHQ-4 differences were observed regarding the population size of the participants' home community. Social participation of immunocompromised persons in our study increased after COVID-19 vaccination. Therefore, social participation should be explored further, especially with regards to the impact of vaccination on groups with a high health risk."],["dc.identifier.doi","10.3389/fpubh.2022.877623"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/111155"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","2296-2565"],["dc.relation.issn","2296-2565"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","The Impact of COVID-19 Vaccination on the Social Participation of Immunocompromised Persons – Results of a Multicenter Observational Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Vahldiek, Kai"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Grimmelmann, Imke"],["dc.creator.author","Jacqueline Niewolik"],["dc.creator.author","Marie Mikuteit"],["dc.creator.author","Anne Cossmann"],["dc.creator.author","Kai Vahldiek"],["dc.creator.author","Ralf Gutzmer"],["dc.creator.author","Frank Müller"],["dc.creator.author","Dominik Schröder"],["dc.creator.author","Stephanie Heinemann"],["dc.creator.author","Georg M.N. Behrens"],["dc.creator.author","Alexandra Dopfer-Jablonka"],["dc.creator.author","Sandra Steffens"],["dc.creator.author","Imke Grimmelmann"],["dc.date.accessioned","2022-05-25T04:34:16Z"],["dc.date.available","2022-05-25T04:34:16Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Immunogenicity of SARS-CoV-2 vaccines is modestly impaired in cancer patients due to a generally weakened immune system. Immune checkpoint inhibitors (ICI) are expected to enhance immune response. This has already been described to be the case in influenza vaccines, and first data about COVID-19 vaccines show a trend in this direction. Aim: We aimed to investigate the immune response of patients with melanoma under ICI therapy after COVID-19 vaccination. Patients and Methods: In the Skin Cancer Center Hanover (Germany), we recruited 60 patients with advanced melanoma who either received ICI therapy during or before the vaccination period. Serological blood analysis was performed using quantitative ELISA for Anti-SARS-CoV-2 spike protein 1 IgG antibodies. Results: We did not observe an enhanced humoral immune response in patients under active or past ICI therapy after COVID-19 vaccination. Nevertheless, there is a tendency of higher antibody levels when ICI therapy was received within the last 6 months before vaccination. Subgroup analysis revealed that patients in our study population under ongoing targeted therapy during vaccination period had significantly higher median antibody levels than patients without any active antitumor treatment. Conclusion: Melanoma patients under ICI therapy show comparable antibody response after SARS-CoV-2 vaccination to healthy health care professionals. This finding is independent of the timing of ICI therapy."],["dc.identifier.doi","10.1159/000524894"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108255"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","Immunogenicity of COVID-19 vaccination in melanoma patients under immune checkpoint blockade"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","189"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Medical Informatics and Decision Making"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Albrink, Klara"],["dc.contributor.author","Joos, Carla"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Noack, Eva Maria"],["dc.date.accessioned","2022-07-20T05:33:26Z"],["dc.date.available","2022-07-20T05:33:26Z"],["dc.date.issued","2022"],["dc.date.updated","2022-07-25T11:18:53Z"],["dc.description.abstract","Abstract Background With the help of digital tools patients\\’ medical histories can be collected quickly and transferred into their electronic medical records. This information can facilitate treatment planning, reduce documentation work, and improve care. However, it is still unclear whether the information collected from patients in this way is reliable. In this study, we assess the accuracy of the information collected by patients using an app for medical history taking by comparing it with the information collected in a face-to-face medical interview. We also study the app\\’s usability from the patients\\’ point of view and analysing usage data. Methods We developed a software application (app) for symptom-oriented medical history taking specialized for general practice. Medical history taking will take place involving patients with acute somatic or psychological complaints (1) using the app and (2) verbally with trained study staff. To assess the perceived usability, patients will complete a questionnaire for the System Usability Scale. We will collect sociodemographic data, information about media use and health literacy, and app usage data. Discussion Digital tools offer the opportunity to improve patient care. However, it is not self-evident that the medical history taken by digital tools corresponds to the medical history that would be taken in an interview. If simply due to a design flaw patients answer questions about signs and symptoms that indicate possible serious underlying conditions \\‘wrong\\’, this could have severe consequences. By additionally assessing the app\\’s usability as perceived by a diverse group of patients, potential weaknesses in content, design and navigation can be identified and subsequently improved. This is essential in order to ensure that the app meets the need of different groups of patients. Trial registration German Clinical Trials Register DRKS00026659 , registered Nov 03 2021. World Health Organization Trial Registration Data Set, https://trialsearch.who.int/Trial2.aspx? TrialID = DRKS00026659."],["dc.identifier.citation","BMC Medical Informatics and Decision Making. 2022 Jul 19;22(1):189"],["dc.identifier.doi","10.1186/s12911-022-01928-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112526"],["dc.language.iso","en"],["dc.publisher","BioMed Central"],["dc.relation","dasi – Digital assistierte Informationserfassung vor der Sprechstunde"],["dc.relation.issn","1472-6947"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights.holder","The Author(s)"],["dc.subject","App"],["dc.subject","Digital medical history taking"],["dc.subject","Primary care"],["dc.subject","User friendliness"],["dc.title","Obtaining patients’ medical history using a digital device prior to consultation in primary care: study protocol for a usability and validity study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]